Using viruses to fight viruses: New approach eliminates 'dormant' HIV-infected cells

December 18, 2017, The Ottawa Hospital
Researchers at The Ottawa Hospital and the University of Ottawa have discovered that the Maraba virus, or MG1, can target and destroy the kind of HIV-infected cells that standard antiretroviral therapies can't reach. Lead author Dr. Jonathan Angel, senior scientist and infectious disease physician at The Ottawa Hospital, and professor at the University of Ottawa. Credit: The Ottawa Hospital

While Ottawa researchers are known for their work on cancer-fighting viruses, one team is applying these viruses to a new target: HIV.

Researchers at The Ottawa Hospital and the University of Ottawa have discovered that the Maraba virus, or MG1, can target and destroy the kind of HIV-infected that standard antiretroviral therapies can't reach. This laboratory discovery was published in the Journal of Infectious Diseases. If this technique works in humans, it might possibly contribute to a cure for HIV.

While daily medications keep the level of HIV virus in the blood low, there is currently no way to totally eliminate dormant HIV-infected cells from the body. If a person living with HIV stops taking antiretroviral medications, these hidden viruses rapidly rebound.

These latently HIV-infected cells are hard to target because they are not distinguishable from . Dr. Jonathan Angel and his team tried a new approach of identifying these dormant cells by using the MG1 virus. This virus attacks cancer cells that have defects in their interferon pathway, which makes the cells more vulnerable to viruses. Dr. Angel and his team previously found that latently HIV-infected cells also have defects in this pathway.

"We thought that because latently HIV-infected cells had similar characteristics to , that the virus would enter and destroy them," said Dr. Angel, senior scientist and infectious disease physician at The Ottawa Hospital, and professor at the University of Ottawa. "It turns out we were right."

Using a number of laboratory models of latently HIV-infected cells, the researchers found that the MG1 virus targeted and eliminated the infected cells, and left unharmed.

While most of these cells in patients are in the lymph nodes and other organs, a tiny number are found in the blood. When the researchers added MG1 to relevant blood cells taken from HIV-positive individuals, the levels of HIV DNA in the sample dropped. This indicated that the HIV-infected cells had been eliminated.

"We know that the Maraba virus is targeting and killing the latently HIV-infected cells, but we don't know exactly how it's doing this," said Dr. Angel, who is also Head of the Division of Infectious Disease. "We think the virus is able to target the cells because of an impaired interferon pathway, but we need to do more research to know for sure."

The research team's next step is to try the in animal models of HIV or move directly to clinical trials pending funding and approvals.

All research at The Ottawa Hospital is supported by generous donors who contribute to hospital priorities, including research to improve patient care and a research chair in gay men's health. The study was also funded by the Department of Medicine, University of Ottawa, Canadian Institutes of Health Research, Canadian Foundation for AIDS Research,

Explore further: Regulatory T cells harbor HIV/SIV virus during antiviral drug treatment

More information: Nischal Ranganath et al, The oncolytic virus, MG1, targets and eliminates latently HIV-1-infected cells: implications for an HIV cure, The Journal of Infectious Diseases (2017). DOI: 10.1093/infdis/jix639

Related Stories

Regulatory T cells harbor HIV/SIV virus during antiviral drug treatment

October 17, 2017
Scientists at Yerkes National Primate Research Center, Emory University have identified an additional part of the HIV reservoir, immune cells that survive and harbor the virus despite long-term treatment with antiviral drugs.

Cancer drug leads to 'drastic decrease' in HIV infection in lung cancer patient

November 30, 2017
Doctors in France have found the first evidence that a cancer drug may be able to eradicate HIV-infected cells in humans.

Synthetic molecule 'kicks and kills' some persistent HIV in mice

September 21, 2017
Scientists have designed a synthetic molecule that can reactivate dormant human immunodeficiency virus (HIV) in mice and lead to the death of some of the infected cells, according to a study published in PLOS Pathogens.

Reservoirs of latent HIV can grow despite effective therapy, study shows

May 30, 2017
Researchers at Johns Hopkins Medicine report new evidence that immune cells infected with a latent form of human immunodeficiency virus (HIV) are able to proliferate, replenishing the reservoir of virus that is resistant ...

A new method for removing cells infected with the AIDS virus

October 2, 2017
With the successful suppression of the AIDS virus (HIV) through medication, the focus turns toward its eradication. Researchers from Kumamoto University in Japan have developed a new compound that is key to the destruction ...

HIV is still growing, even when undetectable in the blood

January 27, 2016
A team of international scientists led by Northwestern University found that HIV is still replicating in lymphoid tissue, even when it is undetectable in the blood of patients on antiretroviral drugs.

Recommended for you

HIV-1 genetic diversity is higher in vaginal tract than in blood during early infection

January 18, 2018
A first-of-its-kind study has found that the genetic diversity of human immunodeficiency virus type 1 (HIV-1) is higher in the vaginal tract than in the blood stream during early infection. This finding, published in PLOS ...

War in Ukraine has escalated HIV spread in the country: study

January 15, 2018
Conflict in Ukraine has increased the risk of HIV outbreaks throughout the country as displaced HIV-infected people move from war-affected regions to areas with higher risk of transmission, according to analysis by scientists.

Researchers offer new model for uncovering true HIV mortality rates in Zambia

January 12, 2018
A new study that seeks to better ascertain HIV mortality rates in Zambia could provide a model for improved national and regional surveillance approaches, and ultimately, more effective HIV treatment strategies.

New drug capsule may allow weekly HIV treatment

January 9, 2018
Researchers at MIT and Brigham and Women's Hospital have developed a capsule that can deliver a week's worth of HIV drugs in a single dose. This advance could make it much easier for patients to adhere to the strict schedule ...

New long-acting, less-toxic HIV drug suppresses virus in humanized mice

January 8, 2018
A team of Yale researchers tested a new chemical compound that suppresses HIV, protects immune cells, and remains effective for weeks with a single dose. In animal experiments, the compound proved to be a promising new candidate ...

Usage remains low for pill that can prevent HIV infection

January 8, 2018
From gritty neighborhoods in New York and Los Angeles to clinics in Kenya and Brazil, health workers are trying to popularize a pill that has proven highly effective in preventing HIV but which—in their view—remains woefully ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.